Mikhail Blagosklonny: The Man Coming In To Help The Field Of Oncology

Mikhail Blagosklonny is a well-known name in the medical field for the contribution that he has had to the field of oncology. By profession, he is a scientist and researcher who has been working in the field of oncology since the start of his career. He began working there soon out of medical school. His first job as a researcher was working for a company known as Ordway. Ordway was an organization that provided researchers with the resources to be able to find more viable treatments for cancer. Since this was exactly the field that Mikhail Blagosklonny was interested in, he shined brilliantly and made quite a few remarkable discoveries during his time there. His research there has been implemented by doctors all over the world. He has given hope to thousands of people who now have a better course of treatment for their cancers. If there is anyone who knows the field of oncology well enough, it has to be Mikhail Blagosklonny.

Mikhail Blagosklonny has always seen the teaching profession as a way to help society and science. While he was working at Ordway, he also started giving lectures on oncology at the New York Medical College. He was seen as one of the most brilliant teachers there. He imparted his knowledge to numerous students who came there to enter the field of oncology and make a difference to people’s lives. His teachings inspired his students to enter into research to help find a cancer cure for a disease that causes so many people to lose their lives.Mikhail Blagosklonny has always been inclined to research and started being interested in oncology very early on in his life. Halfway through his career, Mikhail Blagosklonny made an astonishing discovery that cemented his name in the medical field. While he was researching on the treatments that doctors were at the time giving patients, he came across a chemical called Rapamycin.

This was one of the main ingredients in the medications that doctors were giving people with cancer. His research pointed towards the fact that Rapamycin could be used to increase the life expectancy of people. This was seen as revolutionary because of how little progress was being made in that sector. He then decided to focus on this to give life to a whole new field within the medical and research profession. His research has made way for other researchers, pointing them in a direction that could help potentially one day help improve the life expectancy of people through a simple drug.Even though he stumbled upon something great outside the world of oncology, he has not stopped researching about oncology. Today, he no longer teaches at the New York Medical College, but is, in fact, the head of the oncological department at the Roswell Park Cancer Institute. He is considered to be one of the most revered teachers at the institute and imparts his knowledge and experiences to the students who come there to be oncologists and maybe even oncological researchers.

Tempus Looks for a Solution

In previous years there have been many debates and various discussions about electronic health records. In many parts due to government intervention, the healthcare industry drastically improved and is more in step with today’s technology that it has ever been. There is much more that needs to be done before the industry can be considered cutting edge. In the industry, there are still issues in terms of data collection, digital technology and streamlining accessibility of content. The company Tempus, hopes to help with these issues. The company has created a infrastructure that analyzes a patient’s clinical and molecular data. One of the issues the company faced was in the extremely important patient information is collected and stored. Found and stored as physician or progress notes, they are generally free hand notes from the doctors and are therefore not easy to capture and analyze and more information click here.

Tempus combated this issue by developing analytics software, but making it widely available and affordable was still an issue. How This important information was put together and stored was also a complication that needed a solution. These and other issues were solved via software that was created by Tempus, that provided natural language processing and optical character recognition abilities. The co-founder of Tempus, Eric Lefkofsky, first became aware of a need for solutions in the health record field buecasue of a breast cancer diagnosis he wife received. Going through her treatment process he began to see the need for a more consistent means of collecting patient data using digital technology. His Website And With his background in inovation and technogy, including co founding co founding Uptake Technologies and being a founding partner of Lightbank,a venture fund that invests in disruptive technologies, Eric set out to be a part of a solution to the problem. Mr. Lefkofsky and his wife created the Lefkofsky Family Foundation, a privately owned charity, that has a mission statement of providing advancement in progams that directly benefit the community, and also serves as a Trustee of Lurie Children’s Hospital of Chicago. Eric Lefkofsky has long shown a compassion for helping others and improving his community, so being made aware of such an issue, it would be expected that such a person would attempt to find a solution. Tempus continues to work on innovating solutions in the health information arena and learn more about Eric.

More Visit: https://technewsspy.com/2017/07/24/tempus-eric-lefkofsky-and-the-rise-of-data-enabled-precision-medicine/

Oncotarget: A Peer-review Journal for Scientists

Oncotarget, established in 2010, has provided the scientists and researchers with a platform to publish their research article.

The Journal is a peer-review journal, and that is what makes it unique. Other experienced scientists. Review the different research papers before they are published.

Impact Journals publishes Journal. Experienced and skilled researchers manage the Journal, and that is the reason for the success. The Editors-in-chief are Andrei V. Gudkov and Mikhail Blagosklonny from the Roswell Park Cancer Institute. Download output styles at Endnote.com.

Oncotarget is an open Journal and thus means that the public can easily access new content every week. The primary role of the Journal is to help the authors increase the impact and the value of the research.

Two of the members of Editorial Board; Carlo M Croce, the former Editor-in-Chief of Cancer Research and the Andrew Schally, published 27 articles and ten articles respectively.

Since its inception, four of the Oncotarget members win the Breakthrough Prize, which is the highest award.

The Journal is licensed under the Creative Commons Attribution 3.0 license. The Gordon Research Conference is the official sponsors of the Journal. The Journal seeks to promote a life without diseases. The scientists foster research on basic clinical science to help in fighting diseases.

The Journal is focused on the research on cancer and oncology. However, they also publish other health-related research papers including cardiology, metabolism, cell biology, endocrinology, and pharmacology. It is important for researchers to indicate the category of the research paper.

The Journal adheres to strict submission guidelines. They support different type of papers like research papers and editorial news. The paper editorial news should have a minimum of 800 words. The references should also be one page. It is required for scientists to include a maximum of three co-editors.

There is no limit on the number of website and references that can be included. The publishing fee is $ 3.400. As of February 2017, the fee is $2,850. The editorial team also gives discounts like $1,900 to respective research. There are no refunds given once the fist manuscript has been published. Read more about Oncotarget at Google Scholar.